Curated dataset · n=51 verified deals · Not live market data · Scores are descriptive, not forecasts.

Network graph, deal flow, valuation matrix, and acquirer landscape.

Smith & Nephew Gynecology (Truclear)→Medtronic

Acquisition · Cash · MDT · announced May 18, 2016

View in network
  1. Announced

    May 18, 2016

  2. Closed

    Aug 8, 2016

Economics

Cash()

Pre-deal · pre-deal mark: 2016, year precision · Medtronic 8-K filing, SEC EDGAR — Truclear acquisition

$350M divestiture price (Smith & Nephew press release)

Target

Smith & Nephew Gynecology (Truclear)

Gynecological Surgery · Clinical / therapeutic

HQ London, UK

TRUCLEAR hysteroscopic tissue resection system for minimally invasive treatment of abnormal uterine bleeding — polyps and fibroids; $56M annual revenue at divestiture

  • Smith & Nephew press release (May 18, 2016)
  • Medtronic press release (May 18, 2016)
  • MassDevice deal coverage (Aug 8, 2016 — close confirmed)

Acquirer

Medtronic (MDT)

Gynecological Surgery

HQ Dublin, Ireland

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

TRUCLEAR hysteroscopic system expands minimally invasive GYN portfolio — targets abnormal uterine bleeding (polyps/fibroids) with $56M trailing revenue

Evidence ladder

Press only — no primary filingValue disclosed
  1. Secondary (press / IR)

    Medtronic press release (May 18, 2016)

  2. Secondary (press / IR)

    Smith & Nephew press release (Aug 8, 2016 — close confirmation)

Limitations

  • Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
  • $350M divestiture price (Smith & Nephew press release)
  • Pre-deal valuation sourced from: Medtronic 8-K filing, SEC EDGAR — Truclear acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.

Patient empowerment context

Patient empowerment baseline (HLTH 2022)

No curated mapping — Smith & Nephew Gynecology (Truclear) (Gynecological Surgery). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.

Research workspace (includes heuristic crosswalk) →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.